nacnkcell – Page 3 – ONK Therapeutics

About nacnkcell

This author has not written his bio yet.
But we are proud to say that nacnkcell contributed 44 entries already.

Entries by nacnkcell

ONK Therapeutics and Trinity College Dublin Collaborate in an Enterprise Ireland Funded Project to Optimize Metabolism of NK Cells for Improved Cancer Therapies

08/06/2021

Collaboration between ONK Therapeutics and Dr. David Finlay’s group at Trinity College Dublin, Ireland Two-year Enterprise Ireland Innovation Partnership Programme (IPP) project grant of €373,295 Research to explore metabolic reprogramming and engineering of natural killer (NK) cells for improved cancer therapy Galway, Ireland and San Diego, USA, 8 June 2021 – ONK Therapeutics Ltd, an […]

From Galway to San Diego: ONK Therapeutics’ Aim to Usher in A New Era of Engineered NK Cell Therapies with the Goal to Ultimately Cure Cancer

07/06/2021

JLabs – View full story

ONK inks deal for novel NK cell technology

27/05/2021

The PharmaLetter – View full story

ONK Therapeutics Secures Exclusive Global License to Patent for CISH Knockout in NK Cells for the Treatment of Cancer, from Australia’s WEHI

27/05/2021

Cytokine Inducible SH2 containing protein (CIS; encoded by the gene CISH) is a potent checkpoint in NK cell-mediated tumor immunity CISH knockout (KO) NK cells have been shown to be more efficient in eliminating cancer cells in in-vivo models Exclusive global license to WEHI patent for CISH KO in the field of NK cells builds […]

ONK Therapeutics Enters into a Research Agreement with NUI Galway to Support Optimization of its Dual-Targeted NK Cell Therapy against AML

17/05/2021

Agreement with the National University of Ireland, Galway (NUI Galway), supervised by leading expert in the cellular environment in Acute Myeloid Leukaemia (AML), Dr. Eva Szegezdi Funded by ONK Therapeutics, the research will support engineering and optimization of its dual-targeted NK cell therapy candidate for AML (ONKT104) Aims to explore the potential added benefit of certain gene […]

ONK Therapeutics Appoints Professor Philippe Moreau to its Scientific Advisory Board

08/04/2021

Professor Philippe Moreau brings 20 years of experience in clinical hematology Translational research head at University Hospital of Nantes, France World-renowned expert in multiple myeloma, leading clinical trials Joins US-based SAB members, Prof Malcolm Brenner MD, Ph.D. and Prof Jeffrey Miller MD Galway, Ireland, and San Diego, USA, 8 April 2021 – ONK Therapeutics Ltd, […]

ONK Therapeutics Strengthens its Cell Therapy Manufacturing Process with License for EBV-LCL Feeder Cell Line from NIH to Enhance NK Cell Expansion

18/03/2021

License with NIH for intellectual property for a clinically-validated, GMP grade feeder cell line to enable robust natural killer (NK) cell expansion Enhances ONK Therapeutics’ evolving research efforts to scale up and support clinical trials Galway, Ireland, and San Diego, USA, 18 March 2021 – ONK Therapeutics Ltd, an innovative cell therapy company focused on […]